Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carbop
3 hours ago
- #Small-cell lung cancer
- #Biomarkers
- #Immunotherapy
- Study investigates baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with durvalumab and carboplatin-etoposide.
- Keywords include Circulating PD-L1+ monocytes, Circulating PD-L1+ neutrophils, Circulating immune cells, ES-SCLC, Immunotherapy, and Predictive biomarker.
- Ethics approval obtained from Institut of Recerca Sant Pau institutional ethics committee, adhering to the Declaration of Helsinki. Informed consent was secured from all participants.
- Several authors declare conflicts of interest with pharmaceutical companies, including AstraZeneca, BMS, MSD, Roche, and others.
- Study sponsored by AstraZeneca Farmacéutica Spain S.A.
- References include key studies on SCLC treatment, such as CASPIAN and IMpower133 trials, highlighting advancements in immunotherapy for ES-SCLC.